In the pharmaceutical industry, you might hear the terms “FDF” and “API” frequently used in reference to products. We surely understand this type of jargon, but we certainly can see how the general public would feel overwhelmed looking at those kinds of terminology abbreviations.
Eribulin is a chemotherapy drug. Its full name is eribulin mesylate. Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease.
Darolutamide was approved by FDA on Jul 30, 2019, and approved by the EMA on March 27, 2020, the trade name is Nubeqa. The drug was research by Orinon, the on Jun 2014, Bayer got the global development and commercial right in the world. Its molecular conformation is different from Enzalutamide and Apalutamide, and its unique chemical structure enables this drug to inhibit the growth of cancer cells by blocking the function of androgen receptors by blocking nuclear ectopic.